Borderline HER-2 breast cancer cases: Histochemical versus real-time PCR analysis and impact of different cut-off values

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 4, 2007, Pages 402-412

  Monego, G ^a   Arena, V ^a   Maggiano, N ^a   Costarelli, L ^b   Crescenzi, A ^c   Zelano, G ^a   Amini, M ^b   Capelli, A ^a   Carbone, A ^a,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

FISH; Immunohistochemistry; Interassay correlation; LightCycler; Test validation; Test variability; Threshold value

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 34250173790     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601128934     Document Type: Article

References (40)

1. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
2. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-8.
3. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
4. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
5. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42.
6. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
7. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-8.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-82.
9. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
10. Depowski P, Mulford D, Minot D, Bourne P, McCabe C, McHugh L. Comparative analysis of Her-2/neu protein overexpression in breast cancer using paraffin-embedded tissue and cytologic specimens. Mod Pathol 2002;15:70A.
11. Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, O'Higgins NJ. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 2002;89:262-71.
12. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
13. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9:923-30.
14. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Ueyama Y, Tamaoki N, et al. In vitro and in vivo antitumor effects of a humanized monoclonal antibody against c-erbB-2 product. Br J Cancer 1996;73:1362-5.
15. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol 2003;199:411-17.
16. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-9.
17. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinomas: a combined immunohistochemical and fluorescence in situ hybridisation approach. Mod Pathol 2000;13:866-73.
18. Diaz NM. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 2001;8:415-18.
19. Zarbo RJ, Hammond ME. Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 2003;127:549-53.
20. Ellis IO, Bartlett J, Doesett M, Humphreys S, Jasani B, Miller K, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
21. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridisation (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.
22. Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, et al. Detection of Her-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001;92:2965-74.
23. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R267-73, Epub 26 January 2005.
24. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.
25. Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004;45:207-17.
26. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503.
27. Merkelbach-Bruse S, Waldermann E, Behrens P, Losen I, Buettner R, Friedrichs N. Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 2003;27:1565-70.
28. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-54.
29. Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 2006;6:2.
30. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, Chaffanet M, et al. Comparative multi-methodological measurement of HERBB2 status in breast cancer. J Pathol 2004;202:286-98.
31. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma. J Mol Diagn 2004;6:42-51.
32. O'Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001;115:504-11.
33. Lamy P-J, Nanni I, Fina F, Bibeau F, Roamin S, Dussert C, et al. Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 2006;21:20-9.
34. Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz J-P, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene amplification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005;51:1093-101.
35. Bedard YC, Pollett AF, Leung SW, O'Malley FP. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol 2003;47:979-84.
36. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
37. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Ferenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
39. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Ferenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
40. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9.